Skip to main content
Celcuity Inc. logo

Celcuity Inc. — Investor Relations & Filings

Listed
Ticker · CELC ISIN · US15102K1007 LEI · 25490070W7UU7W2SEY87 US Professional, scientific and technical activities
Open in API
Filings indexed 508 across all filing types
Latest filing 2026-06-10 Call Transcript
Country US United States of America
Listing US CELC · 7 venues

About Celcuity Inc.

https://www.celcuity.com/

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company's approach centers on the PI3K/AKT/mTOR (PAM) pathway, a critical signaling cascade involved in cancer cell growth and survival. Its lead product candidate, gedatolisib, is a potential first-in-class, pan-PI3K and mTORC1/2 inhibitor designed to comprehensively blockade the PAM pathway. Celcuity's pipeline is advancing treatments with a focus on breast and prostate cancers.

Recent filings

Filing Released Lang Actions
Goldman Sachs 47th Annual Global Healthcare Conference 2026
Call Transcript Classification · 100% confidence
2026-06-10 English
8-K
Capital/Financing Update Classification · 91% confidence The document is a Form 8-K current report disclosing the entry into a material definitive agreement for a $575 million convertible senior notes offering, the termination of a loan agreement, and creation of an off‐balance sheet obligation—all relating to capital‐raising and financing activity. This aligns with the "Capital/Financing Update" category (CAP).
2026-06-08 English
424B5
Capital/Financing Update Classification · 90% confidence The document is a 424(b)(5) prospectus supplement for a $500 million convertible senior notes offering due 2032. It is an SEC shelf registration prospectus describing terms of a new debt financing, not an annual report or earnings release. This is a financing offering document, so it fits the Capital/Financing Update category (CAP).
2026-06-05 English
Jefferies Global Healthcare Conference 2026
Call Transcript Classification · 100% confidence
2026-06-04 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an “Issuer Free Writing Prospectus” and “Pricing Term Sheet” for a $500 million convertible senior notes offering. It includes detailed terms of the debt financing (interest rate, maturity, conversion rights, underwriting, use of proceeds, etc.) and supplements the preliminary prospectus under SEC Rules 433 and 424(b). This is a corporate fundraising communication regarding a debt securities offering, which falls squarely under Capital/Financing Update.
2026-06-04 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement (Form 424B5) related to Celcuity Inc.’s offering of $400 million of convertible senior notes due 2032, detailing the terms of the notes, interest, conversion, redemption, listing and underwriting. This is an offering document for a securities issuance (capital raising activity) rather than an earnings release, management report, or regulatory certification. Therefore, it falls under Capital/Financing Update (CAP).
2026-06-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.